U-Pump Named Top 15 Finalist in DCB Open Innovation Challenge 2025

HOUSTON - May 23, 2025 - PRLog -- U-Pump, Inc., a healthtech company developing an AI-powered reusable insulin patch pump, has been selected as one of the Top 15 finalists in the DCB Open Innovation Challenge 2025, hosted by the Diabetes Center Berne (DCB).

U-Pump's innovative approach to diabetes care focuses on affordability, usability, and smart integration. Its patch pump is the first to combine a refillable reservoir, AI-based dosing, and CGM compatibility — all in a reusable form factor. The company aims to radically improve access to insulin therapy worldwide.

"Being recognized by DCB is an important milestone," said Alexander Senkevich, CEO and co-founder of U-Pump. "We're not just building a device — we're shaping the next generation of insulin delivery."

A Smarter, More Accessible Solution

U-Pump's patch pump includes:

• A refillable, cartridge-based reservoir that significantly lowers long-term costs
• The OneMove™ insertion system for single-step, painless setup
• Seamless integration with CGM platforms (Dexcom, Libre) for real-time insights
• An AI-powered bolus calculator to support better glycemic control
• A subscription model that enhances affordability and adherence

Clinical Impact: Preventing DKA, Improving Adherence

U-Pump's intelligent and user-friendly platform is designed to reduce the risk of diabetic ketoacidosis (DKA), improve Time in Range (TIR), and increase therapy adherence — particularly among newly diagnosed patients and those transitioning from multiple daily injections (MDI).

By eliminating friction in setup, daily use, and cost, U-Pump makes insulin therapy more approachable for both patients and healthcare providers.

Traditional pumps can cost $6,000–12,000 per year in devices and consumables. U-Pump targets an annual cost of approximately $2,000, making advanced therapy viable across both developed and emerging healthcare systems.

Regulatory & IP Progress

• Q-submission (Q250943) submitted to the FDA in 2025
• Two provisional U.S. patents filed (with ten more in progress)
• Clinical pilots secured with partners in the U.S. and Israel
• Preparation underway for CE mark and ISO 13485 certification

About U-Pump, Inc.

U-Pump is a MedTech company committed to transforming diabetes care through thoughtful design, accessible technology, and affordability. Headquartered in United States with operations in Israel, U-Pump's mission is to make smart insulin therapy available to millions worldwide.

Clinical pilots are scheduled to begin in Q4 2025 in both the U.S. and Israel.

🔗 https://u-pump.com/